The CD300LD Knockout LoVo Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the LoVo human colon adenocarcinoma epithelial cell line, engineered to disrupt the CD300LD gene. This polyclonal pool provides a heterogeneous loss-of-function model for studying the regulatory roles of CD300LD without requiring single-cell cloning, preserving genetic diversity that may better approximate tumor heterogeneity. The targeted gene disruption enables systematic investigation of CD300LD-dependent signaling pathways in a well-characterized colorectal cancer background.
The LoVo cell line, established from a metastatic site of colon adenocarcinoma, is a widely employed model for colorectal cancer research, particularly in studies of metastasis, invasion, and drug response. These cells harbor a KRAS mutation and exhibit an epithelial morphology, making them suitable for examining the molecular underpinnings of tumor progression and immune evasion. The availability of this knockout model in the LoVo background facilitates direct interrogation of CD300LD function within a clinically relevant oncogenic context.
CD300LD encodes an inhibitory immune receptor containing immunoreceptor tyrosine-based inhibition motifs (ITIMs). Upon engagement by unknown ligands, possibly induced by inflammatory cytokines such as TNF-alpha and LPS, CD300LD recruits the tyrosine phosphatases SHP-1 and SHP-2. These phosphatases dephosphorylate downstream kinases, including Syk, and suppress NF-??B signaling, ultimately dampening inflammatory responses. Through this ITIM-mediated mechanism, CD300LD serves as a negative regulator of immune cell activation and cytokine production.
In the colorectal adenocarcinoma setting, CD300LD may contribute to immune checkpoint regulation by modulating inflammatory signals within the tumor microenvironment. Disruption of CD300LD in LoVo cells provides a platform to assess how loss of this inhibitory receptor affects cytokine secretion, NF-??B activity, and interactions with immune cells. This model allows researchers to explore the role of CD300LD in cancer immune evasion and its potential as a therapeutic target in colorectal cancer or associated inflammatory conditions.
Typical applications include investigating CD300LD??s role in immune checkpoint regulation and cytokine signaling modulation using techniques such as Western blotting, RT-qPCR, immunofluorescence, and flow cytometry. The knockout cells can be employed in functional assays like NF-??B reporter assays, co-culture systems with immune cells to assess immune evasion, and migration/invasion assays to study metastatic behavior. Additionally, the model supports therapeutic target validation in drug discovery programs focused on modulating inhibitory receptor pathways. For further technical details, please contact Ascent Research.
